Intestinal mucosal barrier repair and immune regulation with an AI-developed gut-restricted PHD inhibitor
Ontology highlight
ABSTRACT: Hypoxia-inducible factor-prolyl hydroxylase (HIF-PHD) inhibitors have been approved for treating renal anemia, yet have failed clinical testing for inflammatory bowel disease (IBD) due to lack of efficacy. We use a multimodel multimodal generative AI platform to design an orally gut-restricted selective PHD1/2 inhibitor, which exhibits favorable safety and pharmacokinetic profiles in preclinical studies. ISM012-042 restores intestinal barrier function and alleviates gut inflammation in multiple experimental colitis models.
ORGANISM(S): Mus musculus
PROVIDER: GSE280622 | GEO | 2024/12/11
REPOSITORIES: GEO
ACCESS DATA